Phase 1
Completed N=30
A Study of LY2940680 in Healthy Participants
Healthy Participants
Source: ClinicalTrials.gov NCT01681186 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcomePrimary: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs — 2; 3; 4; 6 Participants
Summary
This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day washout period between each of the participant's doses. The purpose of Part B is to study how much of the study drug, in capsule or tablet form, gets into the bloodstream and how long the body takes to get rid of it. In addition, the effect of food and a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a minimum 7 day washout period between doses. Participants may only enroll in one part. Screening is required within 28 days prior to the start of the study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs |
2; 3; 4; 6; 5; 3 | — |
| PRIMARY Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation |
879; 1170; 776; 1290 | — |
| SECONDARY Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) |
622; 661; 1740; 3360 | — |
| SECONDARY Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax) |
1.5; 2; 2; 2 | — |
| SECONDARY Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax) |
1; 1.5; 3; 1 | — |
| SECONDARY Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)] |
5300; 9440; 22800; 49300 | — |
| SECONDARY Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)] |
9390; 10300; 11200; 9980 | — |
| SECONDARY Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)] |
5340; 9530; 23000; 49800 | — |
| SECONDARY Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)] |
9460; 10300; 11300; 10000 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy sterile males or surgically sterile females or postmenopausal females, as determined by medical history and physical examination
- Body mass index of 18.5 to 32.0 kilograms per meter square (kg/m^2)
- Have clinical laboratory test results within normal reference range
- Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
- Prepared to eat an entire high fat breakfast
Exclusion Criteria
- Are currently enrolled in, have completed or discontinued within the last 30 days from a clinical trial involving an investigational product
- Have known allergies to LY2940680, related compounds or any components of the formulation, or known allergies to lansoprazole (Part B only)
- Have previously completed or withdrawn from this study or any other study investigating LY2940680, and have previously received the investigational product. Participants in Part A are not allowed to participate in Part B
- Have an abnormality in the 12-lead electrocardiogram (ECG)
- Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data (cholecystectomy or appendectomy are allowed if surgery at least 6 months prior to screening)
- Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- Show evidence of hepatitis C and/or positive hepatitis C antibody
- Show evidence of hepatitis B and/or positive hepatitis B surface antigen
- Have used or intend to use over-the-counter or prescription medication within 14 days prior to dosing or during the study. Exception: participants may continue hormone replacement therapy (HRT; estrogen)
- Use of herbal supplements, grapefruit juice, grapefruits, Seville orange juice, Seville oranges, or Starfruit within 7 days prior to dosing or during the study
Data sourced from ClinicalTrials.gov (NCT01681186). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.